Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia
Granules India has reported consolidated financial results for the period ended December 31, 2021
Key takeaways of recent quarter & conference call highlights
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Subscribe To Our Newsletter & Stay Updated
